>> I am picking up from this stunning single case success that dozens of vascular targeting agent Bio houses (like PPHM patent house holds) perhaps have an effective vessel killer in their untested (for wet AMD application) patent inventory.
Perhaps, but that does not follow automatically. Each of these VTA’s still has to be tested and proven in the clinic.
I just picked up some more OXGN at 8.95. Surprised it has not reacted more strongly to today’s news.
Market Data 
Markets 
AI
